What are the most valued startups in the digital health market?
Download our beautiful pitch about the digital health market

In our digital health market deck, you will find everything you need to understand the market
The digital health market includes telehealth providers, clinical software platforms, remote monitoring companies, AI healthcare tools and technology-enabled care businesses.
This ranking tracks the most valuable digital health startups using public market capitalizations, funding-round valuations, acquisition prices and carefully calculated estimates.
We update this digital health startup list every month to reflect new funding rounds, public-market movements, acquisitions and operating developments.
And if you want to better understand this new industry, you can download our pitch covering the digital health market.
A quick summary table
| Metric | Value |
|---|---|
| Most valuable digital health startup | Hims & Hers, $8.1B |
| Second most valuable digital health startup | Hinge Health, $6.9B |
| Median digital health startup valuation | Approximately $400M |
| Share of digital health valuation captured by the top 10 | Approximately 58.8% |
| Top digital health startup valuation vs. median | Approximately 20.3 times |
| Median digital health valuation-to-capital-raised ratio | Approximately 3.4 times |
| Digital health startups valued at $1B+ | 19 |

This market map, featured in our digital health market deck, highlights top companies and startups in the digital health market
Top startups in the digital health market ranked by valuation
Here is an updated table that ranks the top startups in the digital health market based on their latest reported or estimated valuations.
If you want more detaild about their fundraising activity, you can check our list of the startups who have raised the most funding in the digital health market.
| # | Startup Name | What They Do | Current Valuation ($) | Valuation Confidence Level | Valuation Type | Evidence Status | Total Funding ($) | Funding Confidence Level |
|---|---|---|---|---|---|---|---|---|
| 1 | Hims & Hers | Consumer telehealth and pharmacy | $8.1B | Full Confidence | Public Market Cap | Observed | $197M | Strong Confidence |
| 2 | Hinge Health | Digital MSK physical therapy | $6.9B | Full Confidence | Public Market Cap | Observed | $1.1B | Strong Confidence |
| 3 | Abridge | AI clinical documentation platform | $5.0B–$5.8B | Strong Confidence | Announced Private Round Valuation | Estimated | $758M | Full Confidence |
| 4 | Ro | Direct-to-patient telehealth platform | $4.5B–$6.0B | Partial Confidence | Comparables-Based Estimate | Estimated | $1.0B | Strong Confidence |
| 5 | Sword Health | AI virtual MSK care | $3.8B–$4.4B | Strong Confidence | Announced Private Round Valuation | Estimated | $380M | Partial Confidence |
| 6 | Aledade | Value-based primary care network | $3.5B–$4.5B | Strong Confidence | Revenue or ARR Multiple Estimate | Estimated | $721M | Strong Confidence |
| 7 | Innovaccer | Healthcare data and AI cloud | $3.3B–$3.6B | Strong Confidence | Announced Private Round Valuation | Estimated | $675M | Strong Confidence |
| 8 | Athelas | Remote care and billing automation | $2.4B | Strong Confidence | Acquisition Value | Observed | $136M | Partial Confidence |
| 9 | Virta Health | Diabetes reversal virtual care | $2.0B–$2.6B | Strong Confidence | Revenue or ARR Multiple Estimate | Estimated | $374M | Partial Confidence |
| 10 | Included Health | Integrated virtual care navigation | $1.5B–$2.2B | Partial Confidence | Revenue or ARR Multiple Estimate | Estimated | $281M | Partial Confidence |
| 11 | Cedar | Patient billing engagement software | $1.5B–$2.2B | Partial Confidence | Comparables-Based Estimate | Estimated | $326M | Strong Confidence |
| 12 | Maven Clinic | Women’s family virtual clinic | $1.5B–$1.9B | Strong Confidence | Announced Private Round Valuation | Estimated | $425M | Strong Confidence |
| 13 | Omada Health | Virtual chronic care programs | $1.4B | Full Confidence | Public Market Cap | Observed | $450M | Strong Confidence |
| 14 | Cadence | AI chronic care management | $1.2B | Full Confidence | Announced Private Round Valuation | Observed | $241M | Full Confidence |
| 15 | Eucalyptus | Consumer telehealth brand portfolio | $1.2B | Strong Confidence | Acquisition Value | Observed | $103M | Strong Confidence |
| 16 | BioIntelliSense | Medical wearable patient monitoring | $1.0B–$1.3B | Strong Confidence | Announced Private Round Valuation | Estimated | $140M | Strong Confidence |
| 17 | NexHealth | Patient experience API platform | $900M–$1.3B | Partial Confidence | Comparables-Based Estimate | Estimated | $177M | Strong Confidence |
| 18 | FIRE1 | Heart failure monitoring device | $800M–$1.3B | Partial Confidence | Implied Valuation from Raise | Implied | $227M | Partial Confidence |
| 19 | Cerebral | Online mental healthcare | $800M–$1.2B | Partial Confidence | Revenue or ARR Multiple Estimate | Estimated | $462M | Full Confidence |
| 20 | Twin Health | Metabolic digital twin care | $950M | Strong Confidence | Announced Private Round Valuation | Observed | $286M | Strong Confidence |
| 21 | Biofourmis | Remote monitoring digital therapeutics | $750M–$1.1B | Partial Confidence | Comparables-Based Estimate | Estimated | $465M | Strong Confidence |
| 22 | Midi Health | Virtual midlife women’s care | $700M–$1.0B | Strong Confidence | Revenue or ARR Multiple Estimate | Estimated | $149M | Full Confidence |
| 23 | Huma | AI remote patient monitoring | $700M–$1.0B | Partial Confidence | Revenue or ARR Multiple Estimate | Estimated | $281M | Partial Confidence |
| 24 | AKASA | AI healthcare revenue-cycle automation | $700M–$1.0B | Partial Confidence | Comparables-Based Estimate | Estimated | $250M | Partial Confidence |
| 25 | Phreesia | Patient intake engagement platform | $671M | Full Confidence | Public Market Cap | Observed | $276M | Partial Confidence |
| 26 | Genome Medical | Telegenomics care delivery | $500M–$750M | Partial Confidence | Implied Valuation from Raise | Implied | $181M | Partial Confidence |
| 27 | Ada Health | AI symptom assessment platform | $500M–$700M | Partial Confidence | Announced Private Round Valuation | Estimated | $167M | Full Confidence |
| 28 | Wheel | Virtual care infrastructure | $450M–$700M | Low Confidence | Implied Valuation from Raise | Estimated | $216M | Full Confidence |
| 29 | Suki | AI clinical documentation assistant | $500M–$650M | Strong Confidence | Announced Private Round Valuation | Estimated | $165M | Strong Confidence |
| 30 | Doctor On Demand | On-demand virtual care | $400M–$700M | Low Confidence | Proxy-Based Estimate | Estimated | $239M | Strong Confidence |
| 31 | Brightside Health | Virtual mental health care | $450M–$650M | Partial Confidence | Announced Private Round Valuation | Estimated | $111M | Strong Confidence |
| 32 | Fabric | Healthcare access automation | $400M–$650M | Partial Confidence | Implied Valuation from Raise | Estimated | $80M | Full Confidence |
| 33 | Lark | AI chronic care coaching | $400M–$650M | Low Confidence | Comparables-Based Estimate | Estimated | $181M | Partial Confidence |
| 34 | Doctor Anywhere | Regional telehealth and clinics | $350M–$600M | Partial Confidence | Implied Valuation from Raise | Estimated | $176M | Strong Confidence |
| 35 | InfoBionic | Remote cardiac monitoring | $350M–$600M | Partial Confidence | Implied Valuation from Raise | Implied | $126M | Strong Confidence |
| 36 | TytoCare | Remote medical exam devices | $325M–$550M | Partial Confidence | Implied Valuation from Raise | Estimated | $205M | Strong Confidence |
| 37 | Eko Health | AI cardiopulmonary detection | $325M–$525M | Partial Confidence | Implied Valuation from Raise | Implied | $134M | Strong Confidence |
| 38 | Current Health | Remote care management platform | $400M | Strong Confidence | Acquisition Value | Observed | $66M | Strong Confidence |
| 39 | SafelyYou | AI senior fall detection | $300M–$500M | Partial Confidence | Implied Valuation from Raise | Implied | $93M | Strong Confidence |
| 40 | DrFirst | E-prescribing workflow software | $300M–$430M | Partial Confidence | Revenue or ARR Multiple Estimate | Estimated | $165M | Partial Confidence |
| 41 | Vida Health | Virtual cardiometabolic care | $250M–$450M | Partial Confidence | Implied Valuation from Raise | Estimated | $192M | Strong Confidence |
| 42 | 1upHealth | Healthcare data interoperability platform | $280M–$420M | Partial Confidence | Implied Valuation from Raise | Implied | $75M | Strong Confidence |
| 43 | Hazel Health | School-based pediatric telehealth | $275M–$375M | Partial Confidence | Implied Valuation from Raise | Implied | $113M | Partial Confidence |
| 44 | Kyruus | Provider search and scheduling | $260M–$400M | Low Confidence | Comparables-Based Estimate | Estimated | $196M | Strong Confidence |
| 45 | Avi Medical | Hybrid primary care clinics | $250M–$375M | Low Confidence | Implied Valuation from Raise | Implied | $100M | Strong Confidence |
| 46 | Healthie | API-first digital-health infrastructure | $260M–$320M | Strong Confidence | Proxy-Based Estimate | Estimated | $39M | Strong Confidence |
| 47 | Maple | Canadian virtual doctor visits | $225M–$350M | Low Confidence | Comparables-Based Estimate | Estimated | $72M | Strong Confidence |
| 48 | Accurx | Healthcare communication workflow platform | $220M–$350M | Partial Confidence | Implied Valuation from Raise | Implied | $51M | Strong Confidence |
| 49 | eVisit | Enterprise virtual care platform | $200M–$325M | Low Confidence | Implied Valuation from Raise | Implied | $70M | Strong Confidence |
| 50 | CoachCare | Remote patient monitoring software | $200M–$350M | Partial Confidence | Implied Valuation from Raise | Implied | $60M | Partial Confidence |
| 51 | CareStack | Cloud dental practice management | $180M–$300M | Partial Confidence | Comparables-Based Estimate | Estimated | $67M | Partial Confidence |
| 52 | Elation Health | Primary care EHR software | $180M–$270M | Partial Confidence | Revenue or ARR Multiple Estimate | Estimated | $109M | Strong Confidence |
| 53 | Helium Health | African healthcare software financing | $170M–$260M | Partial Confidence | Implied Valuation from Raise | Implied | $42M | Strong Confidence |
| 54 | Nurx | Women’s telehealth and prescriptions | $150M–$250M | Low Confidence | Proxy-Based Estimate | Estimated | $91M | Partial Confidence |
| 55 | Vezeeta | MENA healthcare booking marketplace | $140M–$230M | Low Confidence | Comparables-Based Estimate | Estimated | $65M | Partial Confidence |
| 56 | DrChrono | EHR and practice management | $180M | Strong Confidence | Acquisition Value | Observed | $25M | Partial Confidence |
| 57 | KeyCare | Epic-based virtual care | $180M–$280M | Partial Confidence | Implied Valuation from Raise | Implied | $54M | Partial Confidence |
| 58 | Empatica | Wearable digital biomarkers | $130M–$220M | Low Confidence | Implied Valuation from Raise | Implied | $31M | Strong Confidence |
| 59 | 98point6 | Virtual care software licensing | $120M–$220M | Low Confidence | Acquisition Value | Estimated | $305M | Partial Confidence |
| 60 | Pager | Virtual care navigation platform | $120M–$220M | Low Confidence | Revenue or ARR Multiple Estimate | Estimated | $36M | Partial Confidence |
| 61 | Amwell | Enterprise telehealth platform | $144M | Full Confidence | Public Market Cap | Observed | $1.7B | Partial Confidence |
| 62 | Medici | Doctor-patient messaging telehealth | $100M–$175M | Low Confidence | Implied Valuation from Raise | Implied | $70M | Strong Confidence |
| 63 | Canvas Medical | Developer-first electronic health records | $90M–$150M | Partial Confidence | Implied Valuation from Raise | Implied | $44M | Full Confidence |
| 64 | Wellframe | Digital health-plan member engagement | $80M–$140M | Low Confidence | Acquisition Value | Estimated | $45M | Strong Confidence |
| 65 | HealthTap | Virtual primary care platform | $75M–$125M | Low Confidence | Comparables-Based Estimate | Estimated | $38M | Full Confidence |
| 66 | Practice Fusion | Cloud electronic health records | $100M | Full Confidence | Acquisition Value | Observed | $255M | Partial Confidence |
| 67 | CareCloud | Practice management and billing software | $97M | Full Confidence | Public Market Cap | Observed | $94M | Partial Confidence |
| 68 | Dozee | Contactless hospital patient monitoring | $80M–$110M | Partial Confidence | Implied Valuation from Raise | Implied | $33M | Partial Confidence |
| 69 | Validic | Connected health data platform | $55M–$90M | Low Confidence | Comparables-Based Estimate | Estimated | $32M | Strong Confidence |
| 70 | Welkin Health | Patient relationship management software | $45M–$80M | Low Confidence | Proxy-Based Estimate | Estimated | $30M | Strong Confidence |
| 71 | Particle Health | Health data exchange API | $50M–$70M | Partial Confidence | Proxy-Based Estimate | Estimated | $39M | Full Confidence |
| 72 | Neteera | Contactless vital-sign monitoring | $40M–$65M | Low Confidence | Implied Valuation from Raise | Implied | $22M | Strong Confidence |
| 73 | Lumeon | Automated healthcare care orchestration | $40M–$65M | Strong Confidence | Acquisition Value | Observed | $83M | Partial Confidence |
| 74 | Memora Health | AI-enabled patient care navigation | $25M–$35M | Partial Confidence | Acquisition Value | Estimated | $81M | Partial Confidence |
| 75 | Cloud DX | Remote patient monitoring devices | $0M–$2M | Low Confidence | Proxy-Based Estimate | Estimated | $9M | Low Confidence |

This chart, featured in our digital health market deck, compares the 2026 size of the digital health market with other markets of similar size
Key valuation trends in the digital health market
Insights
- The ten largest digital health companies represent about $43.8B, or 58.8% of the combined valuation in this ranking, showing that market value remains concentrated among a small group of category leaders.
- Hims & Hers has a valuation equal to roughly 41 times its recorded funding, making the consumer telehealth company one of the most capital-efficient businesses in the digital health market.
- Abridge and Suki have a combined midpoint valuation of almost $6.0B after raising $923M, highlighting the valuation premium attached to AI tools integrated directly into clinical workflows.
- Aledade, Omada Health, Cadence and Twin Health represent approximately $7.6B in combined value, confirming that reimbursable and longitudinal chronic-care models remain a major digital health category.
- Eucalyptus, BioIntelliSense and Cadence raised a combined $484M but represent approximately $3.6B in value, producing a valuation-to-funding ratio of about 7.4 times.
- Hims & Hers, Hinge Health and Omada Health represent $16.4B in public-market value, concentrating observable digital health outcomes in consumer care, musculoskeletal treatment and chronic-disease management.
- The leading digital health startup is valued at roughly 20 times the median company, while the top ten capture almost three-fifths of total value, revealing a pronounced gap between leaders and smaller platforms.

This chart, featured in our digital health market deck, shows how Hinge Health captured share in digital health
A few word about our methodology
As you can see, we built a database that ranks startups in the digital health market based on their current valuation.
Estimating digital health startup valuations is not always straightforward. Many companies do not publicly disclose their valuation, and the available information can vary widely depending on the company and its stage.
To build this digital health ranking, we applied a structured valuation methodology and cross-checked information across multiple reliable sources.
Whenever possible, we relied on direct disclosures. These include announced valuations from completed funding rounds, public filings for listed digital health companies, or official acquisition prices.
When a digital health company is publicly listed, we use its current market capitalization as the reference valuation.
If a digital health startup was acquired and no independent valuation can reasonably be estimated today, we use the acquisition price as the main reference point.
When a digital health startup recently raised capital but the valuation was not disclosed, we estimate the implied valuation using typical dilution levels for that stage of fundraising.
In some cases, we also estimate valuations using operating metrics such as revenue, ARR, covered members, patient volumes or customer traction, combined with valuation multiples from comparable digital health companies.
When direct financial data is not available, we may rely on carefully selected comparable startups and other signals such as hiring growth, investor quality, reimbursement coverage, health-system partnerships or product traction.
All estimates follow a strict evidence hierarchy. Recent funding rounds with announced valuations carry the most weight, followed by strong operating metrics and comparable company analysis.
We also carefully evaluate the age of every data point. Recent information carries more weight, while older data is treated cautiously and adjusted conservatively when necessary.
Whenever information is uncertain or incomplete, we clearly distinguish between confirmed facts and reasonable inferences.
Because valuation data is not always fully public, each digital health startup in the ranking is assigned a confidence level based on the reliability, recency and consistency of the available evidence.
Full confidence means the valuation is supported by strong and recent evidence. Strong confidence means the estimate is well supported but includes minor inference. Partial confidence means the estimate relies more heavily on indirect signals. Low confidence means available information is limited or inconsistent.
When confidence is lower, we take a more conservative approach by widening the valuation range. This helps reflect the uncertainty and increases the probability that the true valuation falls within the estimated range.
This reflects how we conduct all our research, including the work behind our report covering the digital health market.
In a world where LLMs hallucinate and unreliable information is everywhere, our goal is simple: provide data you can trust.
If you want the full detail on a specific valuation estimate, feel free to contact us and we will gladly explain.
Finally, know that we update the dataset once per month, so come back here if you need fresh information.

This chart, featured in our digital health market deck, shows annual funding in digital health startups
Related blog posts
- The most recent news in digital health
- The most recent funding news in digital health
- The latest update in digital health
- The evolution of funding activity in digital health
- The main fundraising trends in digital health
Who is the author of this content?
NEW MARKET PITCH TEAM
We track new markets so founders and investors can move fasterWe build living “market pitch” documents for emerging markets: from AI to synthetic biology and new proteins. Instead of digging through outdated PDFs, random blog posts, and hallucinated LLM answers, our clients get a clean, visual, always-updated view of what’s really happening. We map the key players, deals, regulations, metrics and signals that matter so you can decide faster whether a market is worth your time. Want to know more? Check out our about page. You can also follow us on Instagram or on Facebook.
How we created this content 🔎📝
At New Market Pitch, we kept seeing the same problem: when you look at a new market, the data is either missing, paywalled, or buried in 300-page reports that feel like they were written in the 80s. On the other side, LLMs and random blog posts give you confident answers with no sources, and sometimes they just make things up. That’s not good enough when you’re about to invest real money or launch a company.
So we decided to fix the experience. For each market we cover, we build a structured database and update it on a regular basis. We track funding rounds, fund memos, M&A moves, partnerships, new products, policy changes, and the real activity of startups and incumbents. Then we turn all of that into a clear “market pitch” that shows where the opportunities are and how people actually win in that space.
Every key data point is checked, sourced, and put back into context by our team. That’s how we can give you both speed and reliability: fast coverage of new markets, without the usual guesswork.